Infectious disease for the rhinologist
ReviewHumansWith luteolin (ultramicronised palmitoylethanolamide with luteolin, as discussed in the review)
This study tested palmitoylethanolamide together with luteolin (ultramicronised palmitoylethanolamide with luteolin, as discussed in the review). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- A review of the previous 18 months of literature on viral, fungal and bacterial infections of the sinonasal tract
What the authors reported
COVID-19 olfactory dysfunction is reported to vary by variant, with olfactory training remaining the main treatment; platelet-rich plasma injections and oral ultramicronised palmitoylethanolamide plus luteolin are noted to have shown early results. Consensus statements on fungal sinusitis and mixed findings on the nasal microbiome in chronic rhinosinusitis are also summarised.
Limits of this study
A short narrative review; PEA is mentioned in one sentence with no trial numbers or doses. Funding and conflicts not stated in the abstract.
Source
PubMed 37997887 · doi:10.1097/MOO.0000000000000947
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.